Executive Overview Drug patent litigation in the United States is a designed feature of the pharmaceutical market, not a dysfunction. […]

The global pharmaceutical sector is defined by a widening rift between the industrial models of India and China. India holds

The biopharmaceutical sector is shifting its capital allocation toward living medicines. Biologics now represent nearly 50% of the industry’s total

How to determine whether a drug patent has been licensed, who holds commercial rights, and what that means for your

Section 1: What the 505(b)(2) Pathway Actually Offers — and What It Doesn’t The 505(b)(2) New Drug Application is a

A deep-dive technical guide for pharma IP teams, CDMO business development leads, R&D directors, and institutional investors tracking contract manufacturing

The most expensive mistake in pharmaceutical finance is not a bad clinical trial bet or a blown launch forecast. It

Executive Summary: The Structural Transformation of Latin America’s Life Sciences Engine The Brazilian pharmaceutical market, historically viewed through the bifurcated

Every large-scale pharmaceutical acquisition rests on a single economic fact: the target’s revenue is a function of its legal right